Phase II study of Proteasome inhibitor Bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma unspecified PTCLU and cutaneous T-cell lymphoma CTCL.
Phase of Trial: Phase II
Latest Information Update: 25 May 2011
At a glance
- Drugs Bortezomib (Primary)
- Indications Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 25 May 2011 New trial record